- Home
- CNM vs ROIV Comparison
CNM vs ROIV Comparison
Compare CNM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNM
- ROIV
- Stock Information
- Founded
- CNM 1996
- ROIV 2014
- Country
- CNM United States
- ROIV United Kingdom
- Employees
- CNM N/A
- ROIV N/A
- Industry
- CNM Durable Goods
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CNM Consumer Discretionary
- ROIV Health Care
- Exchange
- CNM Nasdaq
- ROIV Nasdaq
- Market Cap
- CNM 9.6B
- ROIV 7.8B
- IPO Year
- CNM 2021
- ROIV N/A
- Fundamental
- Price
- CNM $54.80
- ROIV $10.99
- Analyst Decision
- CNM Buy
- ROIV Buy
- Analyst Count
- CNM 11
- ROIV 4
- Target Price
- CNM $57.91
- ROIV $17.50
- AVG Volume (30 Days)
- CNM 1.9M
- ROIV 5.1M
- Earning Date
- CNM 06-10-2025
- ROIV 05-29-2025
- Dividend Yield
- CNM N/A
- ROIV N/A
- EPS Growth
- CNM N/A
- ROIV N/A
- EPS
- CNM 2.13
- ROIV N/A
- Revenue
- CNM $7,441,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CNM $5.39
- ROIV N/A
- Revenue Next Year
- CNM $4.42
- ROIV N/A
- P/E Ratio
- CNM $25.74
- ROIV N/A
- Revenue Growth
- CNM 11.03
- ROIV N/A
- 52 Week Low
- CNM $37.22
- ROIV $8.73
- 52 Week High
- CNM $58.29
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CNM 60.30
- ROIV 52.59
- Support Level
- CNM $53.52
- ROIV $10.59
- Resistance Level
- CNM $55.08
- ROIV $11.37
- Average True Range (ATR)
- CNM 1.25
- ROIV 0.32
- MACD
- CNM 0.07
- ROIV -0.01
- Stochastic Oscillator
- CNM 93.24
- ROIV 52.23
About CNM Core & Main Inc.
Core & Main Inc is a specialty distributor focusing on water, wastewater, storm drainage, and fire protection products and services. Catering to municipalities, private water companies, and contractors, it serves municipal, non-residential, and residential markets nationwide. Its diverse product line includes pipes, valves, fittings, storm drainage products, fire protection products, and meter products. Revenue is principally generated from pipes, valves, and fittings. The company operates across three construction sectors: municipal, non-residential, and residential, contributing to reliable infrastructure development nationwide.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.